- BioVaxys (BIOV) retains New York City-based Maxim Group as its financial advisor and investment banker
- Maxim will help BioVaxys with strategic planning, assessment of potential strategic alliances and capital requirements, as well as advice regarding a listing on a U.S. stock exchange
- The appointment is intended to enhance shareholder value and transform the company through potential capital market opportunities
- Vancouver-based BioVaxys is a clinical-stage biotechnology company developing viral and oncology vaccine platforms, as well as immuno-diagnostics
- BioVaxys (BIOV) last traded at $0.05 per share
BioVaxys (BIOV) retains New York City-based Maxim Group as its financial advisor and investment banker.
Founded in 2002, Maxim Group is a full-service investment bank and securities and wealth management firm headquartered in mid-town Manhattan. It serves a diverse range of corporate clients, institutional investors and high-net-worth individuals.
Maxim will help BioVaxys with strategic planning, assessment of potential strategic alliances and capital requirements, as well as advice regarding a listing on a U.S. stock exchange.
Management views the appointment as a means to enhance shareholder value and transform the company through potential capital market opportunities.
Consideration to Maxim includes 2,902,236 common shares, which will be subject to a statutory restriction period of four months and one day.
Vancouver-based BioVaxys is a clinical-stage biotechnology company developing viral and oncology vaccine platforms, as well as immuno-diagnostics.
BioVaxys (BIOV) last traded at $0.05 per share.
For full disclaimer information, please click here.
